Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
  • Axel S Merseburger
  • Mario W Kramer
  • Joerg Hennenlotter
  • Perikles Simon
  • Judith Knapp
  • Joerg T Hartmann
  • Arnulf Stenzl
  • Juergen Serth
  • Markus A Kuczyk
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000251957800008&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1002/pros.20688
eISSN
1097-0045
Externe Identifier
  • Clarivate Analytics Document Solution ID: 245TD
  • PubMed Identifier: 18008332
ISSN
0270-4137
Ausgabe der Veröffentlichung
1
Zeitschrift
PROSTATE
Schlüsselwörter
  • prostate cancer
  • progression
  • galectin-3
  • hormone refractory
  • tissue microarray
Paginierung
72 - 77
Datum der Veröffentlichung
2008
Status
Published
Titel
Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer
Sub types
  • Article
Ausgabe der Zeitschrift
68

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Altered expression or loss of function of Galectin‐3 (Gal‐3) was suggested to be involved in the pathogenesis and progression of various human cancer entities. The aim of the present study is to determine the expression of Gal‐3 in prostate tissue emerging from a benign to a malignant, in the beginning hormone‐sensitive and finally hormone‐refractory status to further elucidate the role of this carbohydrate‐binding protein for the pathogenesis and/or progression of malignant prostatic disease.</jats:p></jats:sec><jats:sec><jats:title>MATERIALS AND METHODS</jats:title><jats:p>Five hundred and eighty three tissue samples from malignant, tumor adjacent benign, and histologically benign intra‐prostatic areas, retrieved out of 25 whole mounted prostate cancer (CaP) specimens and additional 95 samples of hormone‐refractory CaP, were processed to tissue microarrays. Immunohistochemical Gal‐3 expression was correlated with clinicopathological parameters among the different tissue entities.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Gal‐3 expression was significantly decreased in the hormone‐sensitive CaP specimens when compared with the respective benign tissue either localized far distant from the malignant lesion (<jats:italic>P</jats:italic> &lt; 0.0001, Wilcoxon test) or directly neighboring the primary tumor (<jats:italic>P</jats:italic> &lt; 0.0001). The staining reaction in the benign tissue areas directly neighboring the primary cancerous lesions differed significantly from the benign glands localized distant from the primary tumors (<jats:italic>P</jats:italic> &lt; 0.001). A statistically highly significant, almost complete loss of Gal‐3 was observed in the hormone‐refractory when compared with the hormone‐sensitive tumors (<jats:italic>P</jats:italic> &lt; 0.0001; mean staining score: 27.7% vs. 8.5%).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>The present investigation clearly indicates decreased expression of Gal‐3 to be substantially involved in the pathogenesis and further progression of CaP from benign prostate glands to a finally hormone‐refractory malignant disease. Prostate 68: 72–77, 2008. © 2007 Wiley‐Liss, Inc.</jats:p></jats:sec>
Autoren
  • Axel S Merseburger
  • Mario W Kramer
  • Jörg Hennenlotter
  • Perikles Simon
  • Judith Knapp
  • Jörg T Hartmann
  • Arnulf Stenzl
  • Jürgen Serth
  • Markus A Kuczyk
DOI
10.1002/pros.20688
eISSN
1097-0045
ISSN
0270-4137
Ausgabe der Veröffentlichung
1
Zeitschrift
The Prostate
Sprache
en
Online publication date
2007
Paginierung
72 - 77
Datum der Veröffentlichung
2008
Status
Published
Herausgeber
Wiley
Herausgeber URL
http://dx.doi.org/10.1002/pros.20688
Datum der Datenerfassung
2023
Titel
Involvement of decreased Galectin‐3 expression in the pathogenesis and progression of prostate cancer
Ausgabe der Zeitschrift
68

Datenquelle: Crossref

Abstract
<h4>Background</h4>Altered expression or loss of function of Galectin-3 (Gal-3) was suggested to be involved in the pathogenesis and progression of various human cancer entities. The aim of the present study is to determine the expression of Gal-3 in prostate tissue emerging from a benign to a malignant, in the beginning hormone-sensitive and finally hormone-refractory status to further elucidate the role of this carbohydrate-binding protein for the pathogenesis and/or progression of malignant prostatic disease.<h4>Materials and methods</h4>Five hundred and eighty three tissue samples from malignant, tumor adjacent benign, and histologically benign intra-prostatic areas, retrieved out of 25 whole mounted prostate cancer (CaP) specimens and additional 95 samples of hormone-refractory CaP, were processed to tissue microarrays. Immunohistochemical Gal-3 expression was correlated with clinicopathological parameters among the different tissue entities.<h4>Results</h4>Gal-3 expression was significantly decreased in the hormone-sensitive CaP specimens when compared with the respective benign tissue either localized far distant from the malignant lesion (P < 0.0001, Wilcoxon test) or directly neighboring the primary tumor (P < 0.0001). The staining reaction in the benign tissue areas directly neighboring the primary cancerous lesions differed significantly from the benign glands localized distant from the primary tumors (P < 0.001). A statistically highly significant, almost complete loss of Gal-3 was observed in the hormone-refractory when compared with the hormone-sensitive tumors (P < 0.0001; mean staining score: 27.7% vs. 8.5%).<h4>Conclusions</h4>The present investigation clearly indicates decreased expression of Gal-3 to be substantially involved in the pathogenesis and further progression of CaP from benign prostate glands to a finally hormone-refractory malignant disease.
Addresses
  • Department of Urology, Eberhard Karls University Tübingen, Germany.
Autoren
  • Axel S Merseburger
  • Mario W Kramer
  • Jörg Hennenlotter
  • Perikles Simon
  • Judith Knapp
  • Jörg T Hartmann
  • Arnulf Stenzl
  • Jürgen Serth
  • Markus A Kuczyk
DOI
10.1002/pros.20688
eISSN
1097-0045
Externe Identifier
  • PubMed Identifier: 18008332
Open access
false
ISSN
0270-4137
Ausgabe der Veröffentlichung
1
Zeitschrift
The Prostate
Schlüsselwörter
  • Prostate
  • Humans
  • Prostatic Neoplasms
  • Disease Progression
  • Galectin 3
  • Androgens
  • Protein Array Analysis
  • Immunohistochemistry
  • Aged
  • Middle Aged
  • Male
Sprache
eng
Medium
Print
Paginierung
72 - 77
Datum der Veröffentlichung
2008
Status
Published
Datum der Datenerfassung
2007
Titel
Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
Sub types
  • Research Support, Non-U.S. Gov't
  • Journal Article
Ausgabe der Zeitschrift
68

Datenquelle: Europe PubMed Central

Abstract
BACKGROUND: Altered expression or loss of function of Galectin-3 (Gal-3) was suggested to be involved in the pathogenesis and progression of various human cancer entities. The aim of the present study is to determine the expression of Gal-3 in prostate tissue emerging from a benign to a malignant, in the beginning hormone-sensitive and finally hormone-refractory status to further elucidate the role of this carbohydrate-binding protein for the pathogenesis and/or progression of malignant prostatic disease. MATERIALS AND METHODS: Five hundred and eighty three tissue samples from malignant, tumor adjacent benign, and histologically benign intra-prostatic areas, retrieved out of 25 whole mounted prostate cancer (CaP) specimens and additional 95 samples of hormone-refractory CaP, were processed to tissue microarrays. Immunohistochemical Gal-3 expression was correlated with clinicopathological parameters among the different tissue entities. RESULTS: Gal-3 expression was significantly decreased in the hormone-sensitive CaP specimens when compared with the respective benign tissue either localized far distant from the malignant lesion (P < 0.0001, Wilcoxon test) or directly neighboring the primary tumor (P < 0.0001). The staining reaction in the benign tissue areas directly neighboring the primary cancerous lesions differed significantly from the benign glands localized distant from the primary tumors (P < 0.001). A statistically highly significant, almost complete loss of Gal-3 was observed in the hormone-refractory when compared with the hormone-sensitive tumors (P < 0.0001; mean staining score: 27.7% vs. 8.5%). CONCLUSIONS: The present investigation clearly indicates decreased expression of Gal-3 to be substantially involved in the pathogenesis and further progression of CaP from benign prostate glands to a finally hormone-refractory malignant disease.
Autoren
  • Axel S Merseburger
  • Mario W Kramer
  • Jörg Hennenlotter
  • Perikles Simon
  • Judith Knapp
  • Jörg T Hartmann
  • Arnulf Stenzl
  • Jürgen Serth
  • Markus A Kuczyk
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/18008332
DOI
10.1002/pros.20688
ISSN
0270-4137
Ausgabe der Veröffentlichung
1
Zeitschrift
Prostate
Schlüsselwörter
  • Aged
  • Androgens
  • Disease Progression
  • Galectin 3
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Prostate
  • Prostatic Neoplasms
  • Protein Array Analysis
Sprache
eng
Country
United States
Paginierung
72 - 77
Datum der Veröffentlichung
2008
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2008
Titel
Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
68

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge